---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000037"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-05-24T23:59:59+00:00"
generated_at: "2026-06-01T08:43:33.233053+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Elicio reports preliminary Phase 1a data for ELI-002 7P: 100% T cell response, biomarker reductions

## Summary
- ELI-002 7P generated mKRAS-specific T cell response in 100% (11/11) evaluable patients; responses against all mutations enrolled.
- At 4.9 mg RP2D, 66.7% (4/6) had both CD8+ and CD4+ responses; biomarker reductions in 71% (5/7) evaluable patients.
- Antigen-spreading observed: T cell responses targeting non-immunizing tumor neoantigens in 100% (6/6) at RP2D.
- No dose-limiting toxicities, no treatment-related serious adverse events or cytokine release syndrome.
- Recommended Phase 2 dose: 4.9 mg AMP-Peptides 7P with 10 mg AMP-CpG-7909.

## SEC filing metadata
- accession: 0001601485-24-000037
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-05-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000037/0001601485-24-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000037/angn-20240523.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000037
- JSON: https://secwatch.observer/filing/0001601485-24-000037.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.